CGIM
DMRA

Cannon Global Investment Management’s Damora Therapeutics DMRA Stock Holding History

Cannon Global Investment Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,300
Closed -$241K – 67
2026
Q1 		$241K Buy
+9,300
New +$239K 0.47% 63

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Cannon Global Investment Management's DMRA Position: Q2 2026 in Review

Cannon Global Investment Management sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 9,300 shares — an estimated $241K sold.

Cannon Global Investment Management first reported a position in DMRA in Q1 2026 and held it in 1 quarter. The position peaked at $241K in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Cannon Global Investment Management reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cannon Global Investment Management sold 9,300 Damora Therapeutics shares in Q2 2026, an estimated $241K.
  • Cannon Global Investment Management first reported a position in Damora Therapeutics in Q1 2026 and held it in 1 quarter.
  • Cannon Global Investment Management's Damora Therapeutics position peaked at $241K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.